posted on 2024-04-03, 16:31authored byMartin Kenny, Alice Y Pollitt, Smita Patil, Dishon Wayne Hiebner, Albert Smolenski, Natalija Lakic, Robert Fisher, Reema Alsufyani, Sebastian Lickert, Viola Vogel, Ingmar SchoenIngmar Schoen
<p><strong>Background:</strong> Active and passive biomechanical properties of platelets contribute substantially to thrombus formation. Actomyosin contractility drives clot contraction required for stabilizing the hemostatic plug. Impaired contractility results in bleeding but is difficult to detect using platelet function tests.</p>
<p><strong>Objectives:</strong> To determine how diminished myosin activity affects platelet functions, including and beyond clot contraction.</p>
<p><strong>Methods:</strong> Using the myosin IIA-specific pharmacologic inhibitor blebbistatin, we modulated myosin activity in platelets from healthy donors and systematically characterized platelet responses at various levels of inhibition by interrogating distinct platelet functions at each stage of thrombus formation using a range of complementary assays.</p>
<p><strong>Results:</strong> Partial myosin IIA inhibition neither affected platelet von Willebrand factor interactions under arterial shear nor platelet spreading and cytoskeletal rearrangements on fibrinogen. However, it impacted stress fiber formation and the nanoarchitecture of cell-matrix adhesions, drastically reducing and limiting traction forces. Higher blebbistatin concentrations impaired platelet adhesion under flow, altered mechanosensing at lamellipodia edges, and eliminated traction forces without affecting platelet spreading, α-granule secretion, or procoagulant platelet formation. Unexpectedly, myosin IIA inhibition reduced calcium influx, dense granule secretion, and platelet aggregation downstream of glycoprotein (GP)VI and limited the redistribution of GPVI on the cell membrane, whereas aggregation induced by adenosine diphosphate or arachidonic acid was unaffected.</p>
<p><strong>Conclusion:</strong> Our findings highlight the importance of both active contractile and passive crosslinking roles of myosin IIA in the platelet cytoskeleton. They support the hypothesis that highly contractile platelets are needed for hemostasis and further suggest a supportive role for myosin IIA in GPVI signaling.</p>
Funding
Royal College of Surgeons in Ireland (StAR lecturership)
Science Foundation Ireland under the Future Frontiers Programme (19/FFP/6708)
Carol Briggs-Smalley award from the International Council for Standardization in Haematology
Biomedical Vacation Scholarships from the Welcome Trust
Academy of Medical Science springboard award (SBF002/1099)
Summary data may be found in a data supplement available with the online version of this article. For original data, please contact the corresponding author.
Comments
The original article is available at https://www.sciencedirect.com/
This paper has a corrigendum which can be found at https://doi.org/10.1016/j.rpth.2024.102414 and also in the repository at https://hdl.handle.net/10779/rcsi.25714179.v1
Published Citation
Kenny M. et al. Contractility defects hinder glycoprotein VI-mediated platelet activation and affect platelet functions beyond clot contraction. Res Pract Thromb Haemost. 2024;8(1):102322.